Amendments to the claims

1. (Previously Presented) A dihydropyrazolopyridine compound of the formula (I):



(I)

wherein

R^0 is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, phenylsulfinyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group optionally having substituent(s), phenylalkyl optionally having substituent(s), or a group of the formula: $-COOR^8$ wherein R^8 is hydrogen, alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s);

R^1 and R^2 are the same or different and each is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, hydroxy, thiol, halogen, amino, formyl, carboxy, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group or phenylalkyl;

R^3 is

(1) haloalkyl,

(2) cycloalkyl,

(3) phenyl optionally having substituent(s),

(4) aromatic heterocyclic group,

(5) a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring,

(6) a benzene ring fused with a saturated or unsaturated 5 to 7 membered carbocyclic ring containing 1 to 3 heteroatom(s), or

(7) a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring,

wherein the groups of (2) to (7) may have one or more substituent(s), or

a group selected from the groups represented by the following formulas (II) and (III):

(II) (III)

wherein R^6 and R^7 are each phenyl optionally having substituent(s) or an aromatic heterocyclic group,

or R^2 and R^3 in conjunction form a ring optionally containing heteroatom(s), wherein the ring may be fused with a benzene ring optionally having substituent(s);

R^4 is alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, hydrazinocarbonyl, alkylthiocarbonyl, formyl, carbamoyl, alkylthio, phenylthio, alkylsulfinyl, phenylsulfinyl, alkylsulfonyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having substituent(s), an aromatic heterocyclic group optionally having substituent(s), cyano or nitro; and

R^5 is hydrogen, cyano, formyl, alkyl, cycloalkyl, alkoxyalkyl, phenoxyalkyl,

dialkoxyalkyl, hydroxyalkyl, haloalkyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, alkoxycarbonylalkyl, alkoxycarbonylethenyl, aryl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring; or

phenylaminoalkyl,

acyl,

acylalkyl,

aminocarbonyl,

arylaminocarbonyl,

a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent(s),

a saturated 3 to 7 membered carbocyclic ring having substituent(s),

alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent, or

a group of the formula: $-(CR^aR^b)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^a is hydrogen or alkyl, R^b is hydrogen or alkyl, R^{11} is hydrogen, alkyl, alkylsulfonyl, phenylsulfonyl, phenylalkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylalkylsulfinyl, alkoxycarbonyl, phenoxycarbonyl, phenylalkoxycarbonyl, alkylcarbonyl, phenylcarbonyl or phenylalkylcarbonyl, and R^{12} is hydrogen or alkyl, or R^4 and R^5 in conjunction may form a 5 or 6 membered ring optionally containing heteroatom(s),

provided that when R^0, R^1 and R^2 are each hydrogen, R^4 is methoxycarbonyl and R^5 is methyl, then R^3 is not phenyl, 2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-methoxycarbonylphenyl, and when R^5 is alkyl, then R^4 is not alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, cyano or nitro,

or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. (Previously presented) The dihydropyrazolopyridine compound of claim 1, wherein

R^0 is hydrogen, alkyl, acyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl,phenyl optionally having substituent(s), aromatic heterocyclic group optionally having substituent(s), phenylalkyl optionally having substituent(s), or a group of the formula: $-COOR^8$ wherein R^8 is hydrogen, alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s);

R^1 and R^2 are the same or different and each is hydrogen, alkyl, acyl, cycloalkyl, hydroxy, thiol, halogen, amino, formyl, carboxy, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group or phenylalkyl;

R^3 is

(1) haloalkyl,

(2) cycloalkyl,

(3) phenyl optionally having substituent(s),

(4) aromatic heterocyclic group,

(5) a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring,

(6) a benzene ring fused with a saturated or unsaturated 5 to 7 membered carbocyclic ring containing 1 to 3 heteroatom(s), or

(7) a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring,

wherein the groups of (2) to (7) may have one or more substituent(s), or

a group selected from the groups represented by the following formulas (II) and (III):

(II) (III)

wherein R^6 and R^7 are each phenyl optionally having substituent(s) or an aromatic heterocyclic group,

or R^2 and R^3 in conjunction form a ring optionally containing heteroatom(s), wherein the ring may be fused with a benzene ring optionally having substituent(s);

R^4 is alkoxycarbonyl, aminocarbonyl, hydrazinocarbonyl, alkylthiocarbonyl, formyl, carbamoyl, alkylthio, phenylthio, alkylsulfinyl, phenylsulfinyl, alkylsulfonyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, cyano or nitro; and

R^5 is hydrogen, cyano, formyl, alkyl, cycloalkyl, alkoxyalkyl, phenoxyalkyl, dialkoxyalkyl, hydroxyalkyl, haloalkyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, alkoxycarbonylalkyl, alkoxycarbonylethenyl, aryl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring,

or R^4 and R^5 in conjunction may form a 5 or 6 membered ring optionally containing heteroatom(s),

provided that when R^0, R^1 and R^2 are each hydrogen, R^4 is methoxycarbonyl and R^5 is methyl,

then R^3 is not phenyl, 2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-methoxycarbonylphenyl,
or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

3. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^5 is alkyl having 2 to 8 carbon atoms, cycloalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, phenyl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

4. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^1 is hydrogen, alkyl, phenyl optionally having substituent(s), an aromatic heterocyclic group or phenylalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

5. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^2 is hydrogen or alkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

6. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^3 is phenyl optionally having 1 to 3 substituent(s), naphthyl, 2,1,3-benzoxadiazol-4-yl or 3,4-dihydro-2H-benzopyran-8-yl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

7. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^4 is alkoxycarbonyl having 2 to 5 carbon atoms, cyano or nitro, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

8. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^5 is alkyl having 2 to 4 carbon atoms, cyclopropyl, phenyl, thienyl or hydroxyalkyl, or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

9. (Original) The dihydropyrazolopyridine compound of claim 2, wherein R^2 and R^3 in conjunction form a ring containing sulfur atom and the ring is condensed with a benzene ring optionally having substituent(s), or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

10. (Previously presented) The dihydropyrazolopyridine compound of claim 2, wherein R^0 is hydrogen or a group of the formula: -$COOR^8$ wherein R^8 is alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s), or an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

11. (Original) The dihydropyrazolopyridine compound of claim 2, which is selected from the group consisting of
(32) ethyl 4,7-dihydro-4-(2-methoxyphenyl)-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(47) ethyl 4-(2-chloro-3-trifluoromethylphenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(66) ethyl 4,7-dihydro-4-(naphthalen-1-yl)-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(73) ethyl 4-(3,4-dihydro-2H-benzopyran-8-yl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(87) ethyl 4-(2-chlorophenyl)-4,7-dihydro-6-(thiophen-2-yl)-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(116) ethyl 4-(2,1,3-benzoxadiazol-4-yl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(122) 4-(2,3-dichlorophenyl)-4,7-dihydro-5-nitro-6-propyl-2H-pyrazolo[3,4-b]pyridine,

(140) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
(147) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-phenyl-2H-pyrazolo[3,4-b]pyridine,
(158) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-phenyl-2H-pyrazolo[3,4-b]pyridine,
(171) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(thiophen-2-yl)-2H-pyrazolo[3,4-b]pyridine,
(182) ethyl 4-(2-bromo-3-nitrophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(183) ethyl 4-(2-bromo-3-cyanophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(189) 4-(2-bromo-3-nitrophenyl)-5-cyano-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine,
(205) ethyl 2-tert-butoxycarbonyl-4-(2-chlorophenyl)-4,7-dihydro-6-propyl-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(240) ethyl 4-(2,1,3-benzoxadiazol-4-yl)-6-ethyl-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine-5-carboxylate,
(257) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-hydroxymethyl-2H-pyrazolo[3,4-b]pyridine,
(260) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-isopropyl-2H-pyrazolo[3,4-b]pyridine,
(264) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-isopropyl-2H-pyrazolo[3,4-b]pyridine, and
(268) 4-(2-bromo-3-cyanophenyl)-5-cyano-6-cyclopropyl-4,7-dihydro-2H-pyrazolo[3,4-b]pyridine,
a tautomer, an optically active form thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

12. **(Previously presented)** The dihydropyrazolopyridine compound of claim 1, wherein R^0 is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, formyl, haloalkyl, aminoalkyl, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl,

phenylsulfinyl, mercaptoalkyl, alkylthioalkyl, acyloxyacetyl, acyloxyalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group optionally having substituent(s), phenylalkyl optionally having substituent(s), or a group of the formula: -$COOR^8$ wherein R^8 is hydrogen, alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s);

R^1 is hydrogen;

R^2 is hydrogen, alkyl, aralkyl, acyl, cycloalkyl, hydroxy, thiol, halogen, amino, formyl, carboxy, cyano, nitro, alkylthio, haloalkyl, aminoalkyl, acylamino, alkoxy, cycloalkoxy, phenoxy, phenylalkoxy, aminoalkoxy, alkoxyalkyl, phenoxyalkyl, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cycloalkoxyalkyl, phenylthio, alkylsulfinyl, alkylsulfonyl, phenylsulfonyl, mercaptoalkyl, alkylthioalkyl, phenyl optionally having substituent(s), aromatic heterocyclic group or phenylalkyl;

R^3 is

(1) haloalkyl,

(2) cycloalkyl,

(3) phenyl optionally having substituent(s),

(4) aromatic heterocyclic group,

(5) a benzene ring fused with a saturated or unsaturated 5 or 6 membered carbocyclic ring,

(6) a benzene ring fused with a saturated or unsaturated 5 to 7 membered carbocyclic ring containing 1 to 3 heteroatom(s), or

(7) a 5 to 7 membered saturated or unsaturated carbocyclic ring containing 1 to 3 heteroatom(s), which is fused with a benzene ring,

wherein the groups of (2) to (7) may have one or more substituent(s), or

a group selected from the groups represented by the following formulas (II) and (III):

(II) (III)

wherein R^6 and R^7 are each phenyl optionally having substituent(s) or an aromatic heterocyclic group,

or R^2 and R^3 in conjunction form a ring optionally containing heteroatom(s), wherein the ring may be fused with a benzene ring optionally having substituent(s);

R^4 is alkoxycarbonyl,
alkylcarbonyl,
alkylsulfonyl,
alkylsulfinyl,
phenylsulfinyl,
phenylsulfonyl,
dialkylphosphinyl,
dialkylphosphonyl,
phenyl optionally having substituent(s),
an aromatic heterocyclic group optionally having substituent(s),
cyano or
nitro; and

R^5 is alkyl,
phenylaminoalkyl,
acyl,
acylalkyl,
aminocarbonyl,
arylaminocarbonyl,
a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent(s),

a saturated 3 to 7 membered carbocyclic ring having substituent(s),
alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent, or
a group of the formula: $-(CR^aR^b)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^a is hydrogen or alkyl, R^b is hydrogen or alkyl, R^{11} is hydrogen, alkyl, alkylsulfonyl, phenylsulfonyl, phenylalkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylalkylsulfinyl, alkoxycarbonyl, phenoxycarbonyl, phenylalkoxycarbonyl, alkylcarbonyl, phenylcarbonyl or phenylalkylcarbonyl, and R^{12} is hydrogen or alkyl,

provided that when R^0, R^1 and R^2 are each hydrogen, R^4 is methoxycarbonyl and R^5 is methyl, then R^3 is not phenyl, 2-chlorophenyl, 3-nitrophenyl, 4-carboxyphenyl or 4-methoxycarbonylphenyl, and when R^5 is alkyl, then R^4 is not alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, cyano or nitro,

or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

13. (Original) The dihydropyrazolopyridine compound of claim 12, wherein
R^4 is alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylsulfonyl, dialkylphosphinyl, dialkylphosphonyl, phenyl optionally having substituent(s), an aromatic heterocyclic group having substituent(s), cyano or nitro, and
R^5 is alkyl, phenylaminoalkyl, acyl, acylalkyl, aminocarbonyl, arylaminocarbonyl, a saturated or unsaturated 4 to 7 membered heterocyclic ring optionally having substituent(s), a saturated 3 to 7 membered carbocyclic ring having substituent(s), alkyl substituted by a saturated or unsaturated 4 to 7 membered ring containing 1 or 2 nitrogen atom(s), which optionally has a substituent, or a group of the formula: $-(CH_2)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^{11} is hydrogen, alkyl, alkylsulfonyl, phenylsulfonyl, phenylalkylsulfonyl, alkylsulfinyl, phenylsulfinyl, phenylalkylsulfinyl, alkoxycarbonyl, phenoxycarbonyl, phenylalkoxycarbonyl, alkylcarbonyl, phenylcarbonyl or phenylalkylcarbonyl, and R^{12} is hydrogen or alkyl,

or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

14. (Original) The dihydropyrazolopyridine compound of claim 12 or 13, wherein R^2 is hydrogen or alkyl, or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

15. (Original) The dihydropyrazolopyridine compound of claim 12 or 13, wherein R^3 is phenyl optionally having 1 to 3 substituent(s), naphthyl, 2,1,3-benzoxadiazol-4-yl or 3,4-dihydro-2H-benzopyran-8-yl, or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

16. (Original) The dihydropyrazolopyridine compound of claim 12 or 13, wherein R^4 is alkoxycarbonyl having 2 to 5 carbon atoms, alkylcarbonyl having 2 to 5 carbon atoms, alkylsulfonyl having 1 to 4 carbon atoms, or alkylsulfinyl having 1 to 4 carbon atoms, or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

17. (Original) The dihydropyrazolopyridine compound of claim 12 or 13, wherein R^5 is a group of the formula: $-(CH_2)_nNR^{11}R^{12}$ wherein n is an integer of 1 to 4, R^{11} is hydrogen, alkyl or alkoxycarbonyl and R^{12} is hydrogen or alkyl, or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

18. (Previously presented) The dihydropyrazolopyridine compound of claim 12 or 13, wherein R^0 is hydrogen or a group of the formula: $-COOR^8$ wherein R^8 is alkyl, aryl optionally having substituent(s) or aralkyl optionally having substituent(s), or an optically active form thereof, or a pharmaceutically acceptable salt thereof.

19. (Original) The dihydropyrazolopyridine compound of claim 12 or 13, which is selected from the group consisting of

(1002) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(piperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1003) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-methylpiperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1011) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-methylmorpholin-2-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1014) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1023) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-(N,N-dimethylamino)cyclohexyl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1027) 6-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,

(1033) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(1-ethylpiperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1037) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(piperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1038) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methylpiperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1041) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methylpiperidin-3-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1046) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(4-methylmorpholin-2-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1048) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,

(1051) 6-(1-acetylpiperidin-4-yl)-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,

(1052) 6-(1-benzoylpiperidin-4-yl)-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,

(1053) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(1-methanesulfonylpiperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,
(1059) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-6-(4-oxocyclohexan-1-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,
(1062) 4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-6-(2-oxocyclohexan-1-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,
(1063) 6-acetylmethyl-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,
(1073) 5-cyano-4,7-dihydro-4-(2,3-(methylenedioxy)phenyl)-6-(piperidin-4-yl)-2*H*-pyrazolo[3,4-*b*]pyridine,
(1075) 4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine-6-carboxylic acid phenylamide,
(1078) 4-(2-chlorophenyl)-5-cyano-4,7-dihydro-6-(4-phenylpiperazin-1-yl)methyl-2*H*-pyrazolo[3,4-*b*]pyridine,
(1081) 6-acetyl-4-(2-bromo-3-cyanophenyl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,
(1082) 6-acetyl-4-(2,1,3-benzoxadiazol-4-yl)-5-cyano-4,7-dihydro-2*H*-pyrazolo[3,4-*b*]pyridine,
(1084) 4-(2-bromo-3-cyanophenyl)-5-(pyridin-2-yl)-4,7-dihydro-6-propyl-2*H*-pyrazolo[3,4-*b*]pyridine,
(1086) 4-(2-chlorophenyl)-5-cyano-4,7-dihydro-6-(pyrrolidin-3-yl)-2*H*-pyrazolo[3,4-*b*]pyridine, and
(1087) 4-(2,1,3-benzoxadiazol-4-yl)-5-(pyridin-2-yl)-4,7-dihydro-6-propyl-2*H*-pyrazolo[3,4-*b*]pyridine,
a tautomer thereof, an optically active form thereof, or a pharmaceutically acceptable salt thereof.

20-21. (Cancelled)

22. (Original) A pharmaceutical composition comprising a dihydropyrazolopyridine compound of claim 1 or 2, an optically active form thereof, a pharmaceutically acceptable salt thereof or a

hydrate thereof, and a pharmaceutically acceptable additive.

23. (Original) A pharmaceutical composition comprising a dihydropyrazolopyridine compound of claim 12 or 13, an optically active form thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive.

24. (Original) A glycogen synthase kinase-3 beta inhibitor comprising a compound selected from the group consisting of a dihydropyrazolopyridine compound of claim 1 or 2, an optically active form thereof, a pharmaceutically acceptable salt thereof and a hydrate thereof.

25. (Original) A glycogen synthase kinase-3 beta inhibitor comprising a compound selected from the group consisting of a dihydropyrazolopyridine compound of claim 12 or 13, an optically active form thereof and a pharmaceutically acceptable salt thereof.

26-31. (Cancelled)

32. (New) An optically active form at 4-position of a dihydropyrazolopyridine compound of claim 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.

33. (New) An optically active form at 4-position of a dihydropyrazolopyridine compound of claim 12 or 13, or a pharmaceutically acceptable salt thereof.

34. (New) A pharmaceutical composition comprising a dihydropyrazolopyridine compound of claim 32, a pharmaceutically acceptable salt thereof or a hydrate thereof, and a pharmaceutically acceptable additive.

35. (New) A pharmaceutical composition comprising a dihydropyrazolopyridine compound of claim 33, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable

additive.

36. (New) A glycogen synthase kinase-3 beta inhibitor comprising a compound selected from the group consisting of a dihydropyrazolopyridine compound of claim 32, a pharmaceutically acceptable salt thereof and a hydrate thereof.

37. (New) A glycogen synthase kinase-3 beta inhibitor comprising a compound selected from the group consisting of a dihydropyrazolopyridine compound of claim 33 and a pharmaceutically acceptable salt thereof.

38. (New) A method for treatment of Alzheimer's disease or diabetes, which comprises administering an effective amount of the composition of claim 22 or 23 to a patient in need thereof.

39. (New) A method for treatment of Alzheimer's disease or diabetes, which comprises administering an effective amount of the composition of claim 34 or 35 to a patient in need thereof.